An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?
- PMID: 31807275
- PMCID: PMC6891939
- DOI: 10.2217/mmt-2019-0011
An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?
Abstract
Management of later stage melanoma has undergone significant changes. Sentinel node biopsy has long been an accepted method of staging, but two recent randomized-controlled trials have provided an evidence base for decision making about completion lymphadenectomy. They showed no survival advantage in further surgery for patients with positive sentinel node biopsies. There is now no evidence to support completion lymphadenectomy in the majority of patients, and this is reflected in international practice guidelines.
Keywords: DeCOG-SLT; MSLT-2; lymph node; lymphadenectomy; melanoma; sentinel node.
© 2019 Jennifer Downs.
Conflict of interest statement
Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
Similar articles
-
Sentinel Lymph Node Biopsy, Lymph Node Dissection, and Lymphedema Management Options in Melanoma.Clin Plast Surg. 2021 Oct;48(4):607-616. doi: 10.1016/j.cps.2021.05.005. Epub 2021 Jul 2. Clin Plast Surg. 2021. PMID: 34503721 Review.
-
A survey of surgical management of the sentinel node positive melanoma patient in the post-MSLT2 era.J Surg Oncol. 2021 Dec;124(8):1544-1550. doi: 10.1002/jso.26641. Epub 2021 Aug 18. J Surg Oncol. 2021. PMID: 34406652
-
New Zealand patients have a higher melanoma burden in sentinel nodes and completion lymphadenectomy than patients in MSLT-II.J Plast Reconstr Aesthet Surg. 2023 Aug;83:98-105. doi: 10.1016/j.bjps.2023.04.019. Epub 2023 Apr 17. J Plast Reconstr Aesthet Surg. 2023. PMID: 37271003
-
The Role and Necessity of Sentinel Lymph Node Biopsy for Invasive Melanoma.Front Med (Lausanne). 2019 Oct 22;6:231. doi: 10.3389/fmed.2019.00231. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31696119 Free PMC article. Review.
-
The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes).Ann Surg Oncol. 2020 Jan;27(1):15-21. doi: 10.1245/s10434-019-07830-w. Epub 2019 Sep 18. Ann Surg Oncol. 2020. PMID: 31535299 Review.
Cited by
-
Locoregional melanoma: identifying optimal care in a rapidly changing landscape.Melanoma Manag. 2019 Nov 28;6(3):MMT22. doi: 10.2217/mmt-2019-0014. Melanoma Manag. 2019. PMID: 31807273 Free PMC article. No abstract available.
-
Does It Really Pay-Off? Comparison of Lymphadenectomy versus Observational Approach in Skin Melanoma with Positive Sentinel Node Biopsy: Systematic Review and Meta-Analysis.J Clin Med. 2022 Jul 4;11(13):3880. doi: 10.3390/jcm11133880. J Clin Med. 2022. PMID: 35807174 Free PMC article. Review.
References
-
- Snow H. Abstract of a lecture on melanotic cancerous disease. Lancet 140(3607), 872–874 (1892).
-
- Moody JA, Botham SJ, Dahill KE, Wallace DL, Hardwicke JT. Complications following completion lymphadenectomy versus therapeutic lymphadenectomy for melanoma – a systematic review of the literature. Eur. J. Surg. Oncol. 43(9), 1760–1767 (2017). - PubMed
-
- Balch CM, Soong SJ, Ross MI. et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Ann. Surg. Oncol. 7(2), 87–97 (2000). - PubMed
-
- Cascinelli N, Morabito A, Santinami M, Mackie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. Lancet 351(9105), 793–796 (1998). - PubMed
Publication types
LinkOut - more resources
Full Text Sources